The Role of Lipid Biomarkers in Major Depression
AbstractIn the UK, the lifetime-documented prevalence of major depressive disorder (MDD) is currently 10%. Despite its increasing prevalence and devastating impact on quality of life, the pathophysiological mechanisms underpinning MDD remain to be fully elucidated. Current theories of neurobiological components remain incomplete and protein-centric, rendering pharmacological treatment options suboptimal. In this review, we highlight the pivotal role of lipids in intra- and inter-neuronal functioning, emphasising the potential use of lipids as biomarkers for MDD. The latter has significant implications for improving our understanding of MDD at the cellular and circuit level. There is particular focus on cholesterol (high and low density lipoprotein), omega-3, and omega-6 polyunsaturated fatty acids due to established evidence in the literature of a link between atherosclerotic disease and major depression. We argue that there is significant potential scope for the use of such peripheral biomarkers in the diagnosis, stratification and treatment of MDD. View Full-Text
Share & Cite This Article
Parekh, A.; Smeeth, D.; Milner, Y.; Thuret, S. The Role of Lipid Biomarkers in Major Depression. Healthcare 2017, 5, 5.
Parekh A, Smeeth D, Milner Y, Thuret S. The Role of Lipid Biomarkers in Major Depression. Healthcare. 2017; 5(1):5.Chicago/Turabian Style
Parekh, Amy; Smeeth, Demelza; Milner, Yasmin; Thuret, Sandrine. 2017. "The Role of Lipid Biomarkers in Major Depression." Healthcare 5, no. 1: 5.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.